Literature DB >> 22589645

Radioiodine I-131 for the therapy of graves' disease.

Malik Mumtaz1, Lim Shueh Lin, Khaw Chong Hui, Amir Sharifuddin Mohd Khir.   

Abstract

Graves' disease is a common cause of hyperthyroidism. Treatment options for Graves' disease include antithyroid medication, surgery or radioactive iodine (I-31) or RAI. This review will focus on the approach to RAI therapy; discussing dose selection, patient preparation, and consideration before and after administering RAI, examining aspects of pre-treatment with antithyroid medication as well as discussing possible adverse events including hypothyroidism and possible worsening of thyroid-associated opthalmopathy. Follow-up is lifelong with the aim of ensuring the patient remains euthyroid or on replacement therapy if there is evidence of hypothyroidism. While there are controversies in treatment of thyrotoxicosis with RAI, with appropriate patient selection and regular follow-up, radioiodine is a safe and effective modality in achieving high cure rates.

Entities:  

Keywords:  Graves’ disease; medical sciences; radioactive iodine; thyroid; treatment

Year:  2009        PMID: 22589645      PMCID: PMC3336179     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  58 in total

1.  Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials.

Authors:  Martin A Walter; Matthias Briel; Mirjam Christ-Crain; Steen J Bonnema; John Connell; David S Cooper; Heiner C Bucher; Jan Müller-Brand; Beat Müller
Journal:  BMJ       Date:  2007-02-19

2.  Treating thyrotoxicosis in pregnant or potentially pregnant women.

Authors:  M J O'Doherty; P R McElhatton; S H Thomas
Journal:  BMJ       Date:  1999-01-02

3.  Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism.

Authors:  R E Imseis; L Vanmiddlesworth; J D Massie; A J Bush; N R Vanmiddlesworth
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

4.  Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism.

Authors:  Saara Metso; Pia Jaatinen; Heini Huhtala; Anssi Auvinen; Heikki Oksala; Jorma Salmi
Journal:  J Clin Endocrinol Metab       Date:  2007-03-20       Impact factor: 5.958

5.  Long-term follow-up of treatment of thyrotoxicosis by three different methods.

Authors:  J A Franklyn; J Daykin; Z Drolc; M Farmer; M C Sheppard
Journal:  Clin Endocrinol (Oxf)       Date:  1991-01       Impact factor: 3.478

6.  The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine.

Authors:  P H Davies; J A Franklyn; J Daykin; M C Sheppard
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

Review 7.  The effects of lithium therapy on thyroid and thyrotropin-releasing hormone.

Authors:  J H Lazarus
Journal:  Thyroid       Date:  1998-10       Impact factor: 6.568

8.  Leukaemia incidence after iodine-131 exposure.

Authors:  P Hall; J D Boice; G Berg; G Bjelkengren; U B Ericsson; A Hallquist; M Lidberg; G Lundell; A Mattsson; J Tennvall
Journal:  Lancet       Date:  1992-07-04       Impact factor: 79.321

9.  A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism.

Authors:  C S Bal; Ajay Kumar; R M Pandey
Journal:  Thyroid       Date:  2002-05       Impact factor: 6.568

Review 10.  Diagnostic criteria for Graves' ophthalmopathy.

Authors:  G B Bartley; C A Gorman
Journal:  Am J Ophthalmol       Date:  1995-06       Impact factor: 5.258

View more
  14 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 2.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

Review 3.  Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.

Authors:  Wojciech Szlasa; Natalia Janicka; Natalia Sauer; Olga Michel; Bernadetta Nowak; Jolanta Saczko; Julita Kulbacka
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

4.  Nodular Graves' disease with medullary thyroid cancer.

Authors:  Shoukat Hussain Khan; Tanveer Ahmed Rather; Rumana Makhdoomi; Dharmender Malik
Journal:  Indian J Nucl Med       Date:  2015 Oct-Dec

5.  Epidemiology and Clinical Features of Thyroid-associated Orbitopathy in Accra.

Authors:  Edith Mawunyo Ackuaku-Dogbe; Josephine Akpalu; Benjamin Abaidoo
Journal:  Middle East Afr J Ophthalmol       Date:  2017 Oct-Dec

6.  Hypothyroidism and its associated factors after radioactive iodine therapy among patients with hyperthyroidism in the Northeast Coast State of Malaysia.

Authors:  Wan M I Wan Mohamed; Suzila C Sayuti; Nani Draman
Journal:  J Taibah Univ Med Sci       Date:  2018-07-18

7.  Iodine-131 induced hepatotoxicity in previously healthy patients with Grave's disease.

Authors:  Navina Priya Jhummon; Bhavna Tohooloo; Shen Qu
Journal:  Thyroid Res       Date:  2013-03-16

8.  The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of (131)I in Hyperthyroidism.

Authors:  A Hussein Sundawa Kartamihardja; Stepanus Massora
Journal:  World J Nucl Med       Date:  2016 May-Aug

Review 9.  Seeking Optimal Management for Radioactive Iodine Therapy-induced Adverse Effects.

Authors:  Andreas Charalambous
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Oct-Dec

10.  Giant toxic multinodular goiter with dyspnea: A case report.

Authors:  Sujeethra Alaguvelsamy; Sachender Pal Singh; Ravi Ramalingam; Ramalingam Kombupalayam Komarappa Gounder
Journal:  Int J Surg Case Rep       Date:  2020-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.